On 15 July 2016, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the second quarter 2016.
Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 14:00 CET. The event will be hosted by Sobi’s CEO and President, Geoffrey McDonough, and the presentation will be held in English.
The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi’s website prior to the telephone conference.
To participate in the telephone conference, please call:
UK: +44 203 008 9809 SE : +46 8 566 426 93 US: +1 855 831 5948
Live audience URL:
http://event.onlineseminarsolutions.com/r.htm?e=1215499&s=1&k=14AE39DFA233FA34ED318311BDCACC44 (The recording will be made available via the audience URL within three hours after the live broadcast.)
---
About Sobi™
Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
